Emergency & Toxicology

Methemoglobinemia: causes and methylene blue

Clinical Overview and When to Suspect Methemoglobinemia

— Cyanosis unresponsive to supplemental O₂

— Chocolate-brown blood on phlebotomy that does not turn red on exposure to air

— Pulse oximetry stuck around 82–85% regardless of FiO₂

— Recent exposure to oxidizing agents (see chunk 2)

— Acquired (most common): dapsone, benzocaine/lidocaine topical sprays, nitrates/nitrites (including "poppers"), aniline dyes, sulfonamides, primaquine, well water nitrates in infants

— Congenital: cytochrome b5 reductase (NADH-MetHb reductase) deficiency, hemoglobin M variants

— <15%: asymptomatic or mild cyanosis

— 15–30%: headache, fatigue, dizziness, chocolate cyanosis

— 30–50%: dyspnea, confusion, tachycardia

— 50–70%: seizures, coma, acidosis, arrhythmia

— >70%: often fatal

Board pearl: A patient who undergoes transesophageal echo or bronchoscopy with benzocaine spray and develops sudden cyanosis with SpO₂ ~85% has methemoglobinemia until proven otherwise — this is one of the most repeated Step 3 stems.

Step 3 management: First moves are 100% O₂ by nonrebreather, large-bore IV access, co-oximetry ABG (not standard pulse ox), and removal of the offending oxidant while preparing methylene blue 1–2 mg/kg IV for symptomatic patients or MetHb >20–30%.

Definition: Methemoglobinemia is a state in which hemoglobin iron is oxidized from the ferrous (Fe²⁺) to ferric (Fe³⁺) form, producing methemoglobin (MetHb), which cannot bind oxygen and shifts the oxyhemoglobin dissociation curve leftward, impairing tissue O₂ delivery.

Why it matters in the ED: Patients appear profoundly cyanotic and "hypoxic" yet have a normal arterial PaO₂ — the classic "saturation gap" between pulse oximetry (~85%) and calculated SaO₂ from ABG.

When to suspect:

Etiologic categories:

Severity by MetHb %:

Presentation Patterns and Key History

— Benzocaine spray before TEE, EGD, bronchoscopy, or intubation → cyanosis within minutes

— Dapsone for PJP prophylaxis (HIV), leprosy, or dermatitis herpetiformis → subacute fatigue, dyspnea over days

— Topical anesthetics (Hurricaine, Cetacaine) on teething infants or dental procedures

— Nitrate/nitrite recreational use ("poppers," amyl/isobutyl nitrite) in MSM patients

— Well-water nitrates in infants <6 months ("blue baby syndrome") — fetal Hb and immature reductase

— Industrial exposures: aniline dyes, nitrobenzene, nitroglycerin manufacturing

— Phenazopyridine (Pyridium) overdose for UTI dysuria

— Sulfonamides, primaquine, chloroquine, rasburicase (also causes hemolysis in G6PD)

— Acute (minutes–hours): topical anesthetic exposure, nitrite ingestion

— Subacute (days): dapsone, sulfonamides

— Chronic/lifelong: congenital cytochrome b5 reductase deficiency — bluish skin since birth, otherwise asymptomatic

— Recent procedures with topical sprays?

— New medications, especially dapsone, TMP-SMX, phenazopyridine?

— Recreational drug use (inhaled "poppers")?

— Infant feeding history with well water or homemade formula?

— Family history of cyanosis or "blue" relatives?

— G6PD status — relevant because methylene blue can paradoxically cause hemolysis

Key distinction: Cyanosis from cardiopulmonary disease improves with supplemental O₂; methemoglobinemia cyanosis does not. Likewise, sulfhemoglobinemia (sulfa drugs, also dapsone) presents similarly but does not respond to methylene blue — a high-yield differentiator.

Board pearl: An HIV patient on dapsone PJP prophylaxis presenting with progressive dyspnea, low SpO₂ unresponsive to O₂, and a saturation gap on ABG is the single most repeated Step 3 methemoglobinemia stem. Always check the med list.

Classic ED vignettes — memorize these triggers:

Symptom timeline:

Key history questions:

Physical Exam Findings and Hemodynamic Assessment

— Slate-gray or chocolate-brown cyanosis of lips, nail beds, ears, and tongue

— Cyanosis present even at MetHb levels of 10–15% (vs ~5 g/dL deoxyhemoglobin needed for true hypoxic cyanosis)

— Does not improve with 100% O₂ — pathognomonic clue

— Venous and arterial blood both appear chocolate brown; does not redden when shaken in air

— Place a drop on white filter paper and compare to normal blood — classic bedside test

— Tachypnea, dyspnea, anxiety

— Lungs typically clear — distinguishes from pneumonia, ARDS, pulmonary edema

— No hypoxemia on PaO₂ (oxygen tension is normal); the problem is O₂ carrying, not exchange

— Tachycardia from compensatory response

— At MetHb >50%: hypotension, dysrhythmias, ischemic chest pain (especially in CAD patients)

— ECG may show ST changes, T-wave abnormalities from functional anemia

— Mild (20–30%): headache, lightheadedness

— Moderate (30–50%): confusion, lethargy

— Severe (>50%): seizures, coma

— SpO₂ characteristically plateaus around 82–85% regardless of true MetHb level because MetHb absorbs both 660 nm and 940 nm wavelengths equally

— Newer 8-wavelength co-oximeters (Masimo Rad-57) can measure MetHb noninvasively at bedside

Board pearl: The triad of cyanosis + normal lung exam + SpO₂ ~85% refractory to O₂ = methemoglobinemia. If SpO₂ improves with O₂ to 95%+, look for pulmonary or cardiac shunt instead.

Step 3 management: At triage, document dual oximetry plus ABG with co-oximetry simultaneously — the gap quantifies the diagnosis. Place patient on cardiac monitor; severe cases (>50%) need ICU bed assignment before the methylene blue infusion is hung.

Skin and mucosa:

Blood appearance:

Respiratory:

Cardiovascular:

Neurologic:

Pulse oximetry quirk:

Diagnostic Workup — Initial Labs and ABG

— Standard ABG measures dissolved O₂ (PaO₂) and calculates SaO₂ — both will be falsely normal

— Co-oximetry directly measures oxyhemoglobin, deoxyhemoglobin, carboxyhemoglobin, and methemoglobin by spectrophotometry at multiple wavelengths

— Order specifically as "ABG with co-oximetry" or "MetHb level"

— Normal or high PaO₂ (often >400 on supplemental O₂)

— Normal calculated SaO₂ (~99%)

— Measured SaO₂ low (e.g., 75%)

— Saturation gap = calculated SaO₂ − measured SaO₂ >5% → diagnostic

— Metabolic acidosis with elevated lactate if severe (impaired O₂ delivery)

— Usually normal Hb unless concurrent hemolysis (dapsone, G6PD)

— Look for Heinz bodies and bite cells on smear in dapsone toxicity

— Lactate elevation correlates with severity

— Renal/hepatic function for drug clearance and risk stratification

— <20%: observe, remove agent

— 20–30% symptomatic OR >30% regardless: treat

— >50%: urgent treatment, ICU

Key distinction: Carbon monoxide poisoning also produces a saturation gap and normal PaO₂, but co-oximetry distinguishes COHb from MetHb. Both can coexist after smoke inhalation or industrial exposure — always check the full panel.

Board pearl: A pulse ox of 85% that won't budge with 100% O₂ + a "chocolate brown" blood tube on the bench + a calculated SaO₂ of 99% on the ABG = order co-oximetry now. This is the highest-yield diagnostic sequence on Step 3.

CCS pearl: Always order "ABG with co-oximetry" — ordering just "ABG" on the CCS interface will miss the MetHb level.

Co-oximetry ABG is the diagnostic gold standard:

Classic ABG pattern:

CBC:

Chemistry:

Methemoglobin %: reported directly by co-oximeter — guides therapy:

G6PD level: ideally checked, but do not delay methylene blue in life-threatening cases

Glucose: hypoglycemia worsens NADPH reduction capacity

Diagnostic Workup — Advanced and Confirmatory Studies

— Place a drop of patient's blood on white filter paper next to a control drop

— Methemoglobin remains brown even after exposure to air for 30–60 seconds; normal blood turns bright red

— Quick, free, and supports the diagnosis while awaiting co-oximetry

— Uses 8 wavelengths to quantify MetHb and COHb at bedside

— Useful in mass-casualty (smoke inhalation, industrial spills) and pre-hospital screening

— Less accurate at extremes; confirm with lab co-oximetry

— Indicated for chronic/congenital cyanosis without obvious exposure

— Confirms autosomal recessive type I (RBC only) vs type II (generalized, with neurologic disease)

— Identifies hemoglobin M variants — autosomal dominant cyanosis from stabilized ferric Hb

— These patients do not respond to methylene blue and need only reassurance

— Critical before repeat dosing of methylene blue

— G6PD-deficient patients cannot generate NADPH needed for methylene blue to work, AND methylene blue itself is oxidizing → risk of acute hemolysis

— Salicylate, acetaminophen, ethanol if intentional ingestion

— Urine drug screen for nitrites/poppers

— CO level if smoke inhalation

Key distinction: Hb M disease = congenital, family history of cyanosis, no response to methylene blue, otherwise healthy. Cytochrome b5 reductase deficiency type I = responds to methylene blue and ascorbic acid; type II adds intellectual disability and early mortality.

Board pearl: A chronically cyanotic but otherwise well patient with a similarly affected parent and no response to methylene blue has Hb M — order Hb electrophoresis, reassure, no treatment needed.

Bedside filter paper test:

Noninvasive pulse co-oximetry (Masimo Rad-57):

Cytochrome b5 reductase enzyme assay:

Hemoglobin electrophoresis:

G6PD quantitative assay:

Additional studies in toxic exposure:

ECG and troponin: in older patients or those with chest pain — functional anemia can precipitate demand ischemia (type 2 MI)

Risk Stratification and First-Line Management Logic

— Asymptomatic and <20%: remove offending agent, supplemental O₂, observation 4–6 hours, recheck level

— Symptomatic OR >20–30%: methylene blue 1–2 mg/kg IV over 5 minutes

— >50% or severe symptoms (seizure, coma, ischemia): methylene blue plus consider exchange transfusion or hyperbaric O₂ if refractory

— Discontinue the oxidizing agent — sounds obvious but commonly missed on board vignettes (e.g., stop the dapsone)

— 100% O₂ by nonrebreather — maximizes dissolved O₂ delivery even if Hb-bound transport is impaired

— Cardiac monitoring, IV access, continuous co-oximetry

— Underlying anemia (less functional Hb reserve)

— CAD, CHF, COPD — limited compensation

— Pregnancy — fetal vulnerability

— Concurrent CO poisoning — additive O₂ delivery failure

— G6PD deficiency (relative — risk of hemolysis; consider alternative)

— Concurrent serotonergic agents (MAOI-like activity of methylene blue → serotonin syndrome)

— Known hypersensitivity

— Ascorbic acid (vitamin C) 300–1000 mg IV — slow, second-line

— Exchange transfusion — for severe cases or G6PD patients

— Hyperbaric oxygen — refractory or massive cases

— Riboflavin — chronic congenital cases

Step 3 management: The board-correct sequence is (1) stop the agent, (2) 100% O₂, (3) IV access + co-oximetry, (4) methylene blue 1–2 mg/kg IV over 5 min if level >20–30% or symptomatic, (5) repeat dose at 1 hour if no improvement (max ~7 mg/kg total), (6) escalate to exchange transfusion if no response.

Board pearl: A patient on an SSRI who develops methemoglobinemia presents an ethical/clinical dilemma — methylene blue is an MAOI and can trigger serotonin syndrome. Weigh risk; for severe MetHb, give it anyway but monitor closely.

Decision algorithm by MetHb percentage and symptoms:

Always first:

Special triggers to treat aggressively at lower MetHb %:

Contraindications to methylene blue:

Alternatives when methylene blue is contraindicated or ineffective:

Pharmacotherapy — Methylene Blue Mechanism and Dosing

— Methylene blue is reduced by NADPH (via NADPH-MetHb reductase / G6PD pathway) to leukomethylene blue

— Leukomethylene blue then donates electrons to MetHb (Fe³⁺), reducing it back to functional Hb (Fe²⁺)

— Effectively bypasses the deficient cytochrome b5 reductase pathway by using an alternative reductase system

— 1–2 mg/kg IV over 5 minutes (1% solution = 10 mg/mL)

— Onset within 20–60 minutes; recheck MetHb at 1 hour

— Repeat dose 1 mg/kg if MetHb remains >20% or symptoms persist

— Maximum cumulative dose ~7 mg/kg — higher doses paradoxically cause methemoglobinemia and hemolysis

— Flush IV line afterward — methylene blue is irritating

— Renal excretion; urine and sweat turn blue-green (warn patient)

— Half-life ~5 hours

— Crosses placenta and blood-brain barrier

— Blue/green urine and skin discoloration

— Falsely low SpO₂ reading (transient, 1–2 hours)

— Nausea, dysuria, chest tightness

— Headache, dizziness

— Hemolysis in G6PD deficiency (insufficient NADPH)

— Serotonin syndrome when combined with SSRIs, SNRIs, MAOIs, tramadol, meperidine, linezolid

— Hypertension at high doses

— Paradoxical methemoglobinemia at doses >7 mg/kg

— 300–1000 mg IV or PO

— Slow onset (days), useful for congenital or G6PD-deficient patients

— Not adequate for acute severe toxicity

Board pearl: Methylene blue itself transiently lowers pulse ox readings because it absorbs at 668 nm — do not panic; this is expected and self-resolves.

Step 3 management: Before giving methylene blue, document the med list for serotonergic drugs and G6PD status if known. For G6PD-deficient or methylene-blue-refractory cases, escalate to exchange transfusion or hyperbaric O₂.

Mechanism of action:

Dosing:

Pharmacokinetics:

Common adverse effects:

Serious adverse effects:

Second-line: Ascorbic acid:

Procedures and Advanced Management

— Indicated for life-threatening methemoglobinemia (>50–70%) unresponsive to methylene blue, or when methylene blue is contraindicated (G6PD deficiency)

— Removes oxidant-laden RBCs and replaces with fresh donor cells

— Particularly useful in neonates with "blue baby syndrome"

— Requires hematology and pediatric ICU/adult ICU coordination

— Considered for refractory cases or when methylene blue/exchange unavailable

— Increases dissolved plasma O₂ dramatically (independent of Hb)

— Theoretical role; evidence limited; do not delay first-line therapy

— Particularly useful when concurrent CO poisoning complicates picture

— Intubation for airway protection if obtunded

— Vasopressors for hypotension

— Seizure control with benzodiazepines

— Treat acidosis, correct hypoglycemia

— Activated charcoal if oral ingestion of dapsone, nitrites, or aniline within 1 hour

— Multiple-dose activated charcoal (MDAC) specifically for dapsone — enterohepatic recirculation makes serial dosing helpful; reduces dapsone half-life from ~30 to ~12 hours

— Wash skin if dermal exposure (aniline dyes, nitrobenzene)

— Remove contaminated clothing

— Confirm pharmacy has methylene blue on the ED automated dispensing cabinet — many community hospitals do not stock it

— Pre-arranged toxicology / poison control consultation (1-800-222-1222 in US)

CCS pearl: For dapsone-induced methemoglobinemia, the order set is methylene blue + multiple-dose activated charcoal + admit to monitored bed — dapsone's long half-life means rebound methemoglobinemia can occur 12–24 hours later, requiring repeat methylene blue dosing.

Board pearl: A G6PD-deficient patient with severe methemoglobinemia who fails or cannot receive methylene blue → escalate to exchange transfusion, with HBOT as bridge if available.

Exchange transfusion:

Hyperbaric oxygen therapy (HBOT):

Supportive ICU care for severe cases:

GI decontamination:

Removal of topical agents:

Antidote stewardship:

Special Populations — Elderly, Renal, and Hepatic Impairment

— Lower physiologic reserve — symptomatic at lower MetHb levels (often 15–20%)

— Higher risk of demand ischemia (type 2 MI), CHF exacerbation, and stroke from functional anemia

— Treat at lower thresholds; obtain ECG and troponin

— Polypharmacy increases exposure risk: TMP-SMX for UTI, nitrates for angina, phenazopyridine for dysuria

— Methylene blue is renally excreted — accumulation possible in severe CKD/ESRD

— Dapsone and metabolites accumulate in renal failure → prolonged toxicity

— Consider lower or single-dose methylene blue and monitor for serotonergic-like effects

— Hemodialysis does not efficiently remove methemoglobin but may help clear offending agents

— Dapsone hepatic metabolism produces hydroxylamine metabolites — the actual oxidant culprits

— In liver disease, metabolism is altered and toxicity may be unpredictable

— Methylene blue itself is hepatically metabolized to a small degree

— Less functional Hb → smaller MetHb % causes greater physiologic compromise

— Treat aggressively; consider transfusion alongside methylene blue

— More common in African, Mediterranean, Middle Eastern, Southeast Asian men

— Both the trigger drug (primaquine, dapsone, sulfa) and the antidote (methylene blue) can cause hemolysis

— Use ascorbic acid or exchange transfusion instead

— COPD, CHF, CAD patients decompensate quickly — early treatment threshold

Step 3 management: In an elderly polypharmacy patient with cyanosis and SpO₂ 85% on phenazopyridine for UTI, the answer is stop Pyridium, give methylene blue, obtain troponin and ECG, and admit to telemetry — even at MetHb levels of 15–20%.

Board pearl: Always screen for G6PD status by ethnicity history before methylene blue, especially in chronic dapsone users — they are doubly at risk.

Elderly patients:

Renal impairment:

Hepatic impairment:

Anemia comorbidity:

G6PD deficiency:

Cardiopulmonary disease:

Special Populations — Pregnancy, Pediatrics, and Neonates

— Infants <6 months are uniquely vulnerable:

— Fetal Hb more easily oxidized than adult Hb

— Lower cytochrome b5 reductase activity at birth (matures by 4–6 months)

— Higher gastric pH → bacterial conversion of nitrate to nitrite in the gut

— Triggers: well water with nitrate >10 mg/L (EPA limit), homemade vegetable purees (spinach, beets, carrots), topical benzocaine teething gels, dapsone exposure via breast milk

— Presentation: gray-blue cyanosis, irritability, lethargy, poor feeding, tachypnea

— FDA advises against benzocaine-containing teething products in children <2

— Same as adult: 1–2 mg/kg IV over 5 minutes

— Avoid in neonates with severe G6PD deficiency

— Lower doses (0.3–1 mg/kg) sometimes used in neonates due to risk of paradoxical worsening

— Exchange transfusion is preferred for severe neonatal cases or G6PD deficiency

— Methylene blue is Category C/X depending on route:

— Intra-amniotic injection contraindicated — historically caused fetal intestinal atresia, hemolysis, MetHb

— IV use in life-threatening maternal methemoglobinemia is acceptable — maternal survival prioritized

— Common pregnancy triggers: nitrofurantoin, sulfa drugs, topical anesthetics during delivery

— Co-manage with OB and toxicology

— Methylene blue transferred in breast milk — temporarily withhold breastfeeding for ~8 days after a dose, or pump and discard

— Dapsone in breast milk has caused neonatal hemolysis and methemoglobinemia

Board pearl: A 3-month-old with cyanosis, normal cardiac echo, and a history of homemade vegetable formula or well water → think nitrate-induced "blue baby syndrome." Test the water source as part of public health follow-up.

Step 3 management: For pediatric methemoglobinemia, stop the agent, give methylene blue 1 mg/kg IV, admit to PICU, and notify public health/local water authority if well water is implicated.

Infants and "blue baby syndrome":

Pediatric methylene blue dosing:

Pregnancy:

Breastfeeding:

Complications and Adverse Outcomes

— Tissue hypoxia — lactic acidosis, organ dysfunction

— Myocardial ischemia (type 2 MI) in CAD patients from impaired O₂ delivery

— Cerebral hypoxia — seizures, coma, anoxic brain injury

— Arrhythmias — bradycardia, ventricular ectopy at MetHb >50%

— Death at levels >70% if untreated

— Dapsone, primaquine, and other oxidants cause both methemoglobinemia AND oxidative hemolysis

— Smear: Heinz bodies, bite cells, blister cells

— Hgb may drop 24–72 hours after exposure

— Compounding effect: less Hb plus impaired O₂-carrying = severe functional anemia

— Long-half-life drugs (dapsone) cause recurrence 12–24 hours after initial methylene blue dose

— Requires extended observation and repeat dosing

— Hemolysis in G6PD deficiency

— Serotonin syndrome with SSRIs/SNRIs/MAOIs/tramadol/linezolid

— Paradoxical methemoglobinemia at cumulative doses >7 mg/kg

— Phototoxicity, dyspnea, hypertension, transient blue-green urine/sweat

— Exchange transfusion: transfusion reactions, electrolyte shifts, infection

— HBOT: barotrauma (tympanic membrane), seizures (O₂ toxicity)

— Misdiagnosis as pneumonia, PE, cardiac shunt, or anxiety is common when co-oximetry is not ordered

— Repeat use of supplemental O₂ alone wastes time and worsens outcome

Board pearl: Recurrence of cyanosis 12–24 hours after methylene blue in a dapsone overdose is expected and is not treatment failure — give a second dose and continue MDAC. This is a classic Step 3 distractor.

Step 3 management: All severe methemoglobinemia cases require 24-hour monitored observation minimum with repeat co-oximetry at 1, 4, 8, and 24 hours; check CBC for delayed hemolysis.

Direct complications of methemoglobinemia:

Concurrent hemolytic anemia:

Rebound methemoglobinemia:

Methylene blue–related complications:

Procedural complications:

Diagnostic delays:

When to Escalate Care — ICU, Consult, and Inpatient Triage

— Discharge home: asymptomatic patients with MetHb <15%, agent removed, no comorbidities, reliable follow-up in 24–48 hours

— Observation/telemetry admission: MetHb 15–30%, symptomatic but stable, mild comorbidities, single methylene blue dose given

— ICU admission: MetHb >30% with symptoms, MetHb >50% regardless, hemodynamic instability, altered mental status, concurrent hemolysis, G6PD deficiency receiving alternative therapy, ingestion of long-half-life agent (dapsone)

— Toxicology / Poison Control (1-800-222-1222): every case — they advise on dosing, monitoring duration, and rebound risk

— Hematology: congenital cases, exchange transfusion candidates, G6PD-deficient patients

— Pediatrics / Neonatology: all infants

— Maternal-Fetal Medicine: pregnant patients

— Hyperbaric Medicine: refractory or combined CO/MetHb toxicity

— Cardiology: chest pain, ECG changes, type 2 MI

— Stop offending agent → 100% O₂ NRB → IV access ×2 → ABG with co-oximetry → methylene blue 1 mg/kg IV → admit ICU → cardiac monitor → repeat co-oximetry q1h → recheck MetHb at 1 h → repeat methylene blue if needed → CBC at 24 h for delayed hemolysis → toxicology consult

— Notify local public health if well water nitrate source identified

— Report occupational exposure to OSHA

— Report medication errors (wrong-dose benzocaine spray) per hospital safety/risk management

— Community hospital without methylene blue or exchange transfusion capability → transfer to tertiary care with toxicology and HBOT

CCS pearl: Order "Toxicology consult" and "continuous co-oximetry" early — these orders score and demonstrate appropriate escalation. Failure to recheck MetHb level after methylene blue is a common CCS deduction.

Step 3 management: Any dapsone-overdose patient requires minimum 24-hour ICU admission regardless of initial response due to rebound risk.

Disposition thresholds:

Mandatory consultations:

CCS sequence for severe case:

Public health and reporting:

Transfer criteria:

Key Differentials — Same-Category (Hemoglobinopathies and Saturation Gap)

— Source: house fires, faulty furnaces, generators, vehicle exhaust

— Cherry-red skin (uncommon), headache, nausea, confusion

— Pulse ox normal or elevated (false), but CO-Hb on co-oximetry elevated

— Treatment: 100% O₂ via NRB; HBOT for severe, pregnant, neurologic symptoms

— Can coexist with methemoglobinemia in smoke inhalation

— Caused by sulfa drugs, dapsone, phenazopyridine, metoclopramide

— Greenish discoloration; cyanosis with normal PaO₂

— Does NOT respond to methylene blue — key board distinction

— Spontaneously resolves as RBCs turn over (~120 days)

— Co-oximetry: sulfHb may falsely register as MetHb on some machines

— Autosomal dominant; congenital cyanosis since birth

— Stabilized Fe³⁺ state; no response to methylene blue

— Healthy otherwise; diagnosis by Hb electrophoresis

— Autosomal recessive congenital methemoglobinemia

— Type I: RBC-restricted, cosmetic cyanosis, responds to methylene blue or ascorbic acid

— Type II: generalized, with neurologic disability, early death

— Different mechanism (mitochondrial electron transport blockade)

— Normal SpO₂ and PaO₂, profound lactic acidosis, bitter almond breath, cardiovascular collapse

— Treatment: hydroxocobalamin or nitrite-thiosulfate kit (which paradoxically induces MetHb to bind cyanide)

Key distinction:

— Methemoglobinemia: responds to methylene blue

— Sulfhemoglobinemia / Hb M disease: does NOT respond to methylene blue

— CO poisoning: responds to 100% O₂ ± HBOT

— Cyanide: responds to hydroxocobalamin

Board pearl: A patient given methylene blue with no improvement in MetHb level — first reconsider sulfhemoglobinemia, Hb M disease, or G6PD deficiency (failed reduction). Order Hb electrophoresis or sulfHb assay.

Carboxyhemoglobinemia (CO poisoning):

Sulfhemoglobinemia:

Hemoglobin M disease:

Cytochrome b5 reductase deficiency:

Cyanide poisoning:

Key Differentials — Other-Category Causes of Cyanosis

— Pneumonia, ARDS, pulmonary edema: abnormal lung exam, infiltrates on CXR, responds to O₂

— Pulmonary embolism: sudden dyspnea, pleuritic chest pain, tachycardia, hypoxia improves with O₂; elevated D-dimer, CTPA confirms

— Right-to-left intracardiac shunt: Eisenmenger, tetralogy of Fallot — does not improve fully with O₂, but co-oximetry normal

— Severe asthma/COPD: wheezing, abnormal lung exam, hypoxia responds to O₂ + bronchodilators

— Cold exposure, Raynaud's, peripheral vascular disease — extremities only, central mucosa pink

— Shock states — low cardiac output, lactic acidosis, hypotension

— Argyria (silver toxicity): slate-gray skin, normal SpO₂, normal blood color

— Amiodarone-induced blue-gray pigmentation: chronic use, normal saturation

— Methylene blue itself: transient blue skin discoloration after IV dosing

— Elevated Hct >60% may produce mild cyanosis even with normal saturation (more deoxygenated Hb in absolute terms)

— No true cyanosis; SpO₂ normal or high; can mimic dyspnea but ABG shows respiratory alkalosis

— Cyanosis from upper airway obstruction or bronchospasm; responds to epinephrine, O₂

Key distinction: The single most useful bedside discriminator is response to 100% O₂:

— SpO₂ rises to >95%: pulmonary or cardiopulmonary cause

— SpO₂ remains ~85%: methemoglobinemia, CO poisoning, or sulfhemoglobinemia

— Combined with chocolate-brown blood → methemoglobinemia confirmed

Board pearl: A patient with slate-gray skin but normal SpO₂, normal ABG, normal blood color, and chronic colloidal silver supplement use has argyria — no treatment needed beyond stopping the supplement; reassurance.

Central cyanosis with true hypoxemia (low PaO₂):

Peripheral cyanosis:

Pseudocyanosis (no true desaturation):

Polycythemia:

Anxiety / hyperventilation:

Anaphylaxis:

Secondary Prevention and Discharge Planning

— Explicit list of agents to avoid based on individual trigger:

— Topical benzocaine, lidocaine sprays — avoid dental/ENT products containing them

— Nitrate-containing medications — discuss with cardiologist if angina history

— Phenazopyridine (Pyridium) for UTI dysuria

— Inhaled nitrites ("poppers")

— Dapsone — discuss alternative PJP prophylaxis if HIV

— Medical alert bracelet for congenital methemoglobinemia or G6PD deficiency

— Review EHR allergy/adverse reaction list — document methemoglobinemia trigger

— Notify primary care physician and pharmacy

— Consider EHR alert/flag to prevent recurrence

— If continued use is essential (e.g., dermatitis herpetiformis), monitor MetHb levels periodically

— Coadminister cimetidine — inhibits CYP-mediated formation of toxic hydroxylamine metabolites, reduces MetHb formation

— Adjust dose; consider alternatives (sulfapyridine, gluten-free diet)

— Atovaquone 1500 mg daily (preferred alternative)

— Aerosolized pentamidine monthly

— Resume TMP-SMX desensitization if possible

— Daily ascorbic acid 300–1000 mg PO or methylene blue 100–300 mg PO daily

— Riboflavin 20–30 mg/day as adjunct

— Avoid oxidizing drugs lifelong

— Well water testing if nitrate-related infant case

— Occupational health if industrial exposure (aniline, nitrobenzene workers)

Step 3 management: At discharge, document the trigger agent in the allergy list, provide a written avoidance list, and arrange PCP follow-up within 1 week to confirm resolution and review medication reconciliation.

Board pearl: For an HIV patient with dapsone-induced methemoglobinemia, the board-correct alternative PJP prophylaxis is atovaquone.

Patient education at discharge:

Medication reconciliation:

Dapsone-specific counseling:

Alternative PJP prophylaxis for HIV patients with dapsone toxicity:

Congenital methemoglobinemia chronic management:

Public health follow-up:

Follow-Up, Monitoring Parameters, and Counseling

— 24-hour phone or in-person check for delayed hemolysis or rebound methemoglobinemia

— 1-week PCP visit: CBC, basic metabolic panel, medication reconciliation review

— 2–4 weeks: repeat CBC if oxidative hemolysis occurred

— Hematology referral for congenital cases or G6PD deficiency

— Continuous co-oximetry or serial MetHb levels q1–4h after methylene blue

— Cardiac telemetry for severe cases or comorbid CAD

— Daily CBC for 3 days to monitor for delayed hemolysis (especially dapsone)

— Lactate, ABG, electrolytes as needed

— Urine output (methylene blue–induced blue urine is normal; oliguria suggests hemolytic AKI)

— Explain mechanism in plain language: "Your blood couldn't carry oxygen because of a chemical reaction caused by [agent]."

— Reassure that blue/green urine after methylene blue is harmless and transient

— Warn that breastfeeding should be paused for ~1 week after methylene blue

— Discuss family screening if congenital cytochrome b5 deficiency or Hb M variant suspected

— Autosomal recessive (cytochrome b5 reductase) — siblings 25% affected

— Autosomal dominant (Hb M disease) — offspring 50% affected

— Offer genetic counseling referral

— Most acute cases resolve fully within 24–72 hours

— Return to work/school once asymptomatic and MetHb <2%

— Athletes: temporary exercise restriction until anemia resolves

— Confirm transition to alternative PJP agent; document in HIV care plan

— CD4 count and adherence assessment

CCS pearl: Schedule PCP follow-up in 1 week plus hematology referral in 2–4 weeks for any congenital or G6PD-related case — both score on CCS for appropriate continuity.

Board pearl: Recheck MetHb level at discharge (should be <2%) and again at PCP visit if rebound risk exists.

Follow-up cadence after acute episode:

Monitoring parameters during admission:

Counseling points for patient:

Family/genetic counseling:

Rehabilitation / return to activity:

HIV-specific follow-up:

Ethical, Legal, and Patient Safety Considerations

— Benzocaine spray dosing errors are a sentinel safety event — even brief sprays can deliver toxic doses

— Many institutions have removed benzocaine sprays entirely from procedure suites; replaced with lidocaine atomizers or topical viscous lidocaine

— Hospital policy should mandate timed dosing protocols (e.g., <1 second per spray) and co-oximetry availability wherever benzocaine is used

— Benzocaine products carry FDA warnings against use in children <2 (teething gels) due to methemoglobinemia deaths

— Methylene blue carries warnings for serotonin syndrome when combined with serotonergic drugs

— Before procedures using topical anesthetics (TEE, bronchoscopy), disclose risk of methemoglobinemia as a known rare adverse event

— For methylene blue administration, obtain consent if time permits — explain transient blue urine, G6PD risk, serotonin syndrome risk

— Any case of iatrogenic methemoglobinemia (e.g., wrong-dose lidocaine, retained benzocaine spray) should trigger an incident report and root cause analysis

— Document the exposure clearly in the EHR allergy/adverse reaction list to prevent recurrence

— A patient discharged on dapsone or phenazopyridine without explicit education can re-present with severe methemoglobinemia — handoff to PCP must include medication risk discussion

— Pharmacy reconciliation at discharge is mandated by Joint Commission (NPSG)

— Well water nitrate poisoning of infants → notify local/state health department (public health hazard)

— Occupational exposure → OSHA reporting through employer

— Suspected child neglect/abuse if recurrent nitrite exposure in an infant

— Maternal life-threatening methemoglobinemia justifies methylene blue use despite fetal risk — informed shared decision-making when possible

Board pearl: A patient who suffers severe methemoglobinemia after a TEE with benzocaine has grounds for incident reporting, and the institution should consider system-level removal of benzocaine — a Step 3 patient-safety theme.

Patient safety priorities:

FDA boxed warnings:

Informed consent issues:

Medication errors and root cause analysis:

Transition-of-care risk:

Mandatory reporting:

Ethical issue: methylene blue in pregnancy:

High-Yield Associations and Rapid-Fire Clinical Facts

— Dapsone, Benzocaine/topical anesthetics, Nitrates/nitrites, Aniline dyes, Sulfonamides (TMP-SMX), Phenazopyridine, Primaquine/chloroquine, Rasburicase, Nitroglycerin, Metoclopramide (rare)

— Mnemonic: "Dapsone Babies Need Aniline-Free Sulfa-Free Pyridium-Free Primaquine-Free Rasburicase-Free Nitric-Free Lives"

— Saturation gap >5% = diagnostic

— SpO₂ plateau around 82–85% regardless of true MetHb

— Treatment threshold: symptomatic OR MetHb >20–30%

— Methylene blue dose: 1–2 mg/kg IV, max cumulative 7 mg/kg

— Severe MetHb: >50%; lethal: >70%

— TEE/bronchoscopy + benzocaine → methemoglobinemia within minutes

— HIV + dapsone PJP prophylaxis → subacute methemoglobinemia

— Infant + well water → blue baby syndrome

— "Poppers" use in MSM patient → nitrite-induced methemoglobinemia

— Dental local anesthetic + sudden cyanosis → topical anesthetic toxicity

Board pearl: "Chocolate brown blood" + "saturation gap" + "no response to O₂" = methemoglobinemia. These three phrases on a stem make the answer essentially automatic.

Step 3 management: Recognize, remove agent, 100% O₂, methylene blue 1–2 mg/kg IV, escalate to exchange transfusion if refractory or G6PD deficient.

Drug triggers (memorize):

Key numbers:

Classic associations:

Drugs that BOTH cause MetHb AND hemolyze G6PD-deficient patients: dapsone, primaquine, sulfa drugs, nitrofurantoin, phenazopyridine — high-yield overlap

Methylene blue contraindications: G6PD deficiency, concurrent SSRI/SNRI/MAOI/tramadol/linezolid, hypersensitivity

Non-responders to methylene blue: sulfhemoglobinemia, Hb M disease, G6PD deficiency, NADPH-MetHb reductase deficiency, cumulative dose >7 mg/kg

Cimetidine reduces dapsone toxicity by inhibiting CYP-mediated hydroxylamine formation

Atovaquone is the alternative PJP prophylaxis for dapsone-intolerant HIV patients

Cyanide antidote kit (sodium nitrite) intentionally induces MetHb to scavenge cyanide — therapeutic methemoglobinemia

Board Question Stem Patterns

— "A 62-year-old man undergoes TEE for atrial fibrillation. Within 10 minutes of benzocaine spray, his SpO₂ drops to 84% and remains there despite 100% O₂. His blood appears chocolate brown on phlebotomy. ABG: PaO₂ 412, calculated SaO₂ 99%. Next step?"

— Answer: Methylene blue 1–2 mg/kg IV

— "A 38-year-old HIV+ man on dapsone for PJP prophylaxis presents with 3 days of fatigue and dyspnea. SpO₂ 83% on RA, unchanged on NRB. Lungs clear. Co-oximetry: MetHb 32%."

— Answer: Stop dapsone, methylene blue 1 mg/kg IV, switch to atovaquone

— "A 4-month-old infant presents with cyanosis and lethargy. Parents report mixing formula with private well water. SpO₂ 82% unresponsive to O₂. MetHb 28%."

— Answer: Methylene blue 1 mg/kg IV, notify public health re: well water

— "A Mediterranean man with G6PD deficiency develops methemoglobinemia after sulfa antibiotic. MetHb 45%. He receives methylene blue and his Hgb drops with elevated LDH and indirect bilirubin. Next step?"

— Answer: Exchange transfusion (avoid further methylene blue)

— "A 25-year-old man with lifelong slate-blue skin, normal exercise tolerance, and a similarly affected father has MetHb 18%. He receives methylene blue with no improvement."

— Answer: Hemoglobin electrophoresis → Hb M disease; reassurance

— "A patient on sertraline develops methemoglobinemia after benzocaine. After methylene blue, he becomes agitated, hyperthermic, and hyperreflexic."

— Answer: Serotonin syndrome; supportive care, cyproheptadine

— "Patient with dapsone overdose initially responds to methylene blue, but 18 hours later cyanosis recurs."

— Answer: Repeat methylene blue + multiple-dose activated charcoal

Board pearl: When the stem mentions any topical "-caine" spray, dapsone, nitrate, or well water + cyanosis unresponsive to O₂, the answer is almost always methylene blue.

Stem pattern 1 — Procedural exposure:

Stem pattern 2 — HIV / dapsone:

Stem pattern 3 — Pediatric blue baby:

Stem pattern 4 — G6PD trap:

Stem pattern 5 — Hb M disease:

Stem pattern 6 — Serotonin syndrome interaction:

Stem pattern 7 — Recurrent / dapsone rebound:

One-Line Recap

Methemoglobinemia is functional hypoxia from oxidized (Fe³⁺) hemoglobin caused most often by topical anesthetics, dapsone, or nitrates, presenting with chocolate-brown blood and a saturation gap that does not improve with O₂, and treated with IV methylene blue 1–2 mg/kg — except in G6PD deficiency, sulfhemoglobinemia, or Hb M disease, where methylene blue fails or harms.

— Cyanosis refractory to 100% O₂

— SpO₂ plateaued at 82–85% with normal PaO₂ and saturation gap >5% on co-oximetry

— Chocolate-brown blood that does not redden in air

— Stop the oxidizing agent immediately

— 100% O₂ via nonrebreather

— Methylene blue 1–2 mg/kg IV over 5 minutes if symptomatic or MetHb >20–30%

— Repeat at 1 hour if needed; max cumulative 7 mg/kg

— Escalate to exchange transfusion or HBOT if refractory or contraindicated

— G6PD deficiency → use ascorbic acid or exchange transfusion

— Concurrent SSRI/SNRI/MAOI/tramadol/linezolid → risk of serotonin syndrome

— Sulfhemoglobinemia, Hb M disease, NADPH reductase deficiency → no response

— Cumulative dose >7 mg/kg → paradoxical methemoglobinemia

— Benzocaine spray during TEE/bronchoscopy

— Dapsone in HIV patient for PJP prophylaxis (→ atovaquone)

— Well water nitrate exposure in infants <6 months

— Phenazopyridine, sulfa drugs, primaquine, inhaled "poppers"

Step 3 management: Recognize the saturation gap → co-oximetry → methylene blue → admit → 24-hour observation for rebound → discharge with documented allergy, written avoidance list, and PCP follow-up within 1 week.

Board pearl: Chocolate-brown blood + saturation gap + no response to O₂ = methemoglobinemia = methylene blue, unless G6PD-deficient.

Diagnosis triad:

Treatment algorithm:

When methylene blue is wrong or dangerous:

High-yield triggers to recognize on the boards: